Latest From Biotech Now

The BioGENEius Challenge: Priyen Patel

Priyen shaking hand

By Priyen Patel, 2011 U.S. National BioGENEius Media Award Winner Project Title: Over-the-Counter and In Your Water? The Most Effective Filtration of Pharmaceuticals Project Description: Research shows minute concentrations of drugs in 51 million Americans’ water, leading to tumors and reproductive problems in fish and slowing the growth of kidney cells in humans. I focused on filtering ibuprofen and acetaminophen and my results are: the water distiller (100% effective), the activated carbon filter and ion Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO CEO Company Snapshot: ImmunoGen, Inc.

immunogen-thumb

In the latest Company Snapshot for the 2012 BIO CEO & Investor Conference in New York City, we’re profiling ImmunoGen, Inc. which will be presenting at the event. We spoke with ImmunoGen, Inc. CEO Daniel Junius and he outlined his organization’s priorities and challenges as well as how his company differentiates themselves from the competition. Company Snapshot What are the short-term and long-term priorities for your company? Our highest priority today is building and advancing our pipeline Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Is the Polio Vaccine an Anti-Patent Success Story?

polio-vaccine

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization Question from a Reader: Heather: Whether Jonas Salk believed in patenting research or not isn’t important, at least not to me. What I do find important, and hadn’t realized until reading this article, is that the polio vaccine was extremely successful despite the fact that it wasn’t patented. That sounds like an interesting story because it goes against the current dogma of ‘we won’t Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Bill Gates: Embrace Genetic Modification or Starve

Bill Gates

Bill Gates has a terse response to criticism that the high-tech solutions he advocates for world hunger are too expensive or bad for the environment:  Countries can embrace modern seed technology and genetic modification or their citizens will starve. When he was in high school in the 1960s, people worried there wouldn’t be enough food to feed the world, Gates recalled in his fourth annual letter, which was published online on January 24 and reported Read More >

Farmer Gene  |  1 Comment  |  Email This Post
Tags: , , , , , ,